1、目的：探讨咪唑斯汀递减法口服对慢性荨麻疹(CU)症状控制及减少复发的作用。Objective: To investigate the effect of mizolastine on the control of Chronic Urticaria symptoms and the reduction of recurrence, when mizolastine has been orally taken with the gradual dosage decreasing schedule.方法：选取我科两年来门诊就诊的慢性荨麻疹病人 347 例，其中随机选取患者 267 例作为观察组使用
2、口服咪唑斯汀片递减法治疗，80例口服咪唑斯汀片片每日一次作为对照组。4 周后，观察组按照症状改善情况逐渐减量维持至 3 个月，对照组停药。追踪观察至半年。Methods: 347 outpatients of Chronic Urticaria treated in our department in the last two years were included, from which 267 cases were selected as the observation group and were treated with mizolastine, decreasing oral tak
3、ing, another 80 cases were taken as the control group, who took mizolastine orally once per day. 4 weeks later, medication was gradually decreased in accordance with the relieving of symptoms and lasted for 3 month all together, while medication was stopped in the control group. Follow-up observatio
4、n lasted for six months.结果：治疗组 1 月内症状控制率对照组差异无显著性，3 月内及半年复发率复发率明显低于对照组，其差异具统计学意义。Results: The rate of symptom control of the treatment group got no significant difference from that of the control group in the first month, the recurrence rate of the treatment group within three month and half a year
5、was lower than that of the control group, and the difference was statistically significant.结论：咪唑斯汀递减法治疗慢性荨麻疹症状控制率高，病人依从性好，值得临床推广(有很多种不同的翻译方法, 值得研究) 。Conclusion: The decreasing mizolastine treatment of chronic urticaria symptoms gets a high control rate, a good patient compliance, and is worthwhile for spreading in clinical practice.
